PMC/PubMed Indexed Articles
Indexed In
- Academic Journals Database
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- CiteFactor
- Scimago
- Ulrich's Periodicals Directory
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- SWB online catalog
- Virtual Library of Biology (vifabio)
- Publons
- MIAR
- University Grants Commission
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Pre-clinical and clinical development of an interferon beta 1a biosimilar for the treatment of multiple sclerosis
International Conference and Exhibiton on Pharmaceutical Regulatory Affairs
6-7 September 2011 Baltimore, USA
Marcelo Kauffman
Scientific Tracks Abstracts: JBB
Abstract:
B lastoferon? is a pharmaceutical product of interferon beta 1a currently marketed in Argentina and Latin America as a biosimilar to the innovator interferon beta 1a for the treatment of Multiple Sclerosis. Although regulatory requirements for biosimilars are on debate, there is consensus about the necessity to obtain evidence of the eff ectiveness and safety of these drugs on pre-clinical and clinical grounds. In order to fulfi l these requirements, the manufacturer of Blastoferon? has done diff erent studies in animal models and humans that assess the safety and eff ectiveness of this biosimilar in the treatment of Multiple Sclerosis. Among them, it can be mentioned a safety study in Cebus apella primates , a whole-genome comparative pharmacodynamic trial, a comparative relative bioavailability human trial, a comprehensive and intensive pharmacovigilance program with immunogenicity surveillance and a pragmatic post- marketing eff ectiveness clinical trial. Th is presentation will present the results of these studies and discuss challenges and perspectives of the development and marketing of a biosimilar product in emerging markets
Biography :
Dr. Marcelo Kauffman is a neurologist with MSc and PhD degrees in Molecular Biology. He has been the person in charge of the pre-clinical and clinical development of Blastoferon as an advisor of Bio Sidus S.A. Clinical Research Department. He has been the author of 5 papers presenting the results of the different pre-clinical and clinical Blastoferon studies. Currently, he holds the position of Chief of the Neurogenetic Clinic of Hospital JM Ramos Mejia in Buenos Aires, Argentina and is a lecturer in the School of Medicine of the University of Buenos Aires.